

MEDICAMEN Biotech Limited



Regd. & Corp. Office:
1506, Chiranjiv Tower,
43, Nehru Place,
New Delhi - 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),
E-mail: info@medicamen.com
Web: www.medicamen.com
CIN No.: L74899DL1993PLC056594

Ref: STEX/Results/Published-2023-24

Date: 11.11.2023

To

**BSE Limited
Floor 25, P J Towers
Dalal Street
Mumbai-400001**

**National Stock Exchange of India Ltd
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051**

BSE Code-531146

NSE Code: MEDICAMEQ

Company Number: 531146

Sub. : Copy of Publication for Un-audited Financial Results for the quarter and half year ended September 30, 2023

Dear Sir,

Pursuant to regulation 30 & 47 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015 (“the Regulations”), please find enclosed newspaper cutting with regard to the publication of extract of Un-audited Financial Results of the Company for the quarter and half year ended on September 30, 2023 approved by the Board of Directors at their Meeting held on 10.11.2023.

The copy of the results published in the Financial Express and Jansatta dated November 11, 2023 is enclosed.

This is for your information and records.

Kindly acknowledge the receipt.

Thanking You,

Yours truly,

For Medicamen Biotech Limited

**Parul Choudhary
Company Secretary
ACS-44157**

Encl: As above.

1. Basic:	0.60	0.26	0.83	0.60	0.50	0.95	0.60	0.25	0.83	0.60	0.51	0.95
2. Diluted:	0.60	0.26	0.83	0.86	0.50	0.95	0.60	0.25	0.83	0.86	0.51	0.95

EXPLANATORY NOTES:-

The standalone and consolidated financial results of the Company for the quarter and period ended September 30, 2023 have been reviewed and recommended by the Audit Committee and approved by the Board of directors at their respective meetings held on November 09, 2023

The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

The full format of the Quarterly Financial Results are available on the websites of the Stock Exchanges and on Company's Website.

For Rajdarshan Industries Limited

Sd/-

Madhav Doshi,

Director (DIN: 07815416)

Place: Udaipur

Date: 09-11-2023

**MEDICAMEN BIOTECH LTD.**

Regd. Office: 1506, Chiranjiv Tower 43, Nehru Place, New Delhi-110019

CIN: L74899DL 1993PLC056594 E-mail: cs@medicamen.com, Website: www.medicamen.com

Extracts of Standalone and Consolidated Unaudited Financial Results for the Quarter and Half Year ended on 30.09.2023

(Rupees in Lakhs) Except per share data

Sl. No.	Particulars	Standalone						Consolidated					
		Quarter Ended			Half Year Ended			Quarter Ended			Half Year Ended		
		Un-Audited 30.09.2023	Un-Audited 30.06.2023	Un-Audited 30.09.2022	Un-Audited 30.09.2023	Un-Audited 30.09.2022	Audited 31.03.2023	Un-Audited 30.09.2023	Un-Audited 30.06.2023	Un-Audited 30.09.2022	Un-Audited 30.09.2023	Un-Audited 30.09.2022	Audited 31.03.2023
1	Total income from operations (net)	4322.08	4088.26	3405.70	8410.34	6810.73	14034.62	4409.12	4232.23	3405.69	8641.35	6810.72	14332.96
2	Net Profit/ (Loss) for the period (before tax, exceptional and/ or Extraordinary items)	400.04	515.33	414.91	915.37	847.41	1733.28	246.45	468.33	414.19	714.78	846.69	1704.50
3	Net Profit/ (Loss) for the period before tax (after exceptional and/ or Extraordinary items)	400.04	515.33	414.91	915.37	847.41	1733.28	246.45	468.33	414.19	714.78	846.69	1704.50
4	Net Profit/ (Loss) for the period after tax (after exceptional and/ or Extraordinary items)	301.16	441.70	361.12	742.86	719.68	1500.20	147.67	394.70	360.40	542.37	718.96	1472.85
5	Total comprehensive income for the period (Comprising Profit/ (loss) for the period (after tax) and other Comprehensive income (after tax))	301.16	441.70	361.12	742.86	719.68	1500.20	147.67	394.70	360.40	542.37	718.96	1472.85
6	Equity Share Capital	1265.11	1265.11	1265.11	1265.11	1265.11	1265.11	1265.11	1265.11	1265.11	1265.11	1265.11	1265.11
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)												
8	Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operation)												
	Basic:	2.38	3.49	2.85	5.87	5.69	12.04	1.17	3.12	2.85	4.29	5.68	11.82
	Diluted:	2.38	3.49	2.85	5.87	5.69	12.04	1.17	3.12	2.85	4.29	5.68	11.82

Note:

- The Un-audited financial results for the quarter and half year ended have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 10th Nov 2023
- This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- The company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable
- The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 - "Earning per Share"
- The results are not comparable on quarterly or yearly basis as company is regularly incurring capex and filling dossiers with regulatory authorities.
- Limited review report has been carried out by the Statutory Auditors for the above period.
- The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.

For Medicamen Biotech Limited

Sd/-

Rahul Bishnoi

Chairman

Place: New Delhi

Date: 10.11.2023

AMRUTANJAN HEALTH CARE LIMITED

REGD. OFFICE: New No.103 (Old No.42-45), Luz Church Road, Mylapore, Chennai-600 004
email id: investors@amrutanjan.com | website: www.amrutanjan.com | CIN No: L24231TN1936PLC000017

**EXTRACT FROM THE UNAUDITED FINANCIAL RESULTS
FOR THE QUARTER AND SIX MONTHS ENDED 30TH SEPTEMBER 2023**

Date: November 10, 2023

Place: New Delhi

Himanshu Gupta

Managing Director

DIN: 00054019



MEDICAMEN BIOTECH LTD.

Regd. Office: 1506, Chiranjiv Tower 43, Nehru Place, New Delhi-110019

CIN: L74899DL 1993PLC056594 E-mail: cs@medicamen.com, Website: www.medicamen.com

Extracts of Standalone and Consolidated Unaudited Financial Results for the Quarter and Half Year ended on 30.09.2023

(Rupees in Lakhs) Except per share data

Sl. No.	Particulars	Standalone						Consolidated					
		Quarter Ended			Half Year Ended			Quarter Ended			Half Year Ended		
		Un-Audited 30.09.2023	Un-Audited 30.06.2023	Un-Audited 30.09.2022	Un-Audited 30.09.2023	Un-Audited 30.09.2022	Audited 31.03.2023	Un-Audited 30.09.2023	Un-Audited 30.06.2023	Un-Audited 30.09.2022	Un-Audited 30.09.2023	Un-Audited 30.09.2022	Audited 31.03.2023
1	Total income from operations (net)	4322.08	4088.26	3405.70	8410.34	6810.73	14034.62	4409.12	4232.23	3405.69	8641.35	6810.72	14332.96
2	Net Profit/ (Loss) for the period (before tax, exceptional and/ or Extraordinary items)	400.04	515.33	414.91	915.37	847.41	1733.28	246.45	468.33	414.19	714.78	846.69	1704.50
3	Net Profit/ (Loss) for the period before tax (after exceptional and/ or Extraordinary items)	400.04	515.33	414.91	915.37	847.41	1733.28	246.45	468.33	414.19	714.78	846.69	1704.50
4	Net Profit/ (Loss) for the period after tax (after exceptional and/ or Extraordinary items)	301.16	441.70	361.12	742.86	719.68	1500.20	147.67	394.70	360.40	542.37	718.96	1472.85
5	Total comprehensive income for the period (Comprising Profit/ (loss) for the period (after tax) and other Comprehensive income (after tax))	301.16	441.70	361.12	742.86	719.68	1500.20	147.67	394.70	360.40	542.37	718.96	1472.85
6	Equity Share Capital	1265.11	1265.11	1265.11	1265.11	1265.11	1265.11	1265.11	1265.11	1265.11	1265.11	1265.11	1265.11
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)												
8	Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operation)												
	Basic:	2.38	3.49	2.85	5.87	5.69	12.04	1.17	3.12	2.85	4.29	5.68	11.82
	Diluted:	2.38	3.49	2.85	5.87	5.69	12.04	1.17	3.12	2.85	4.29	5.68	11.82

Note:

- The Un-audited financial results for the quarter and half year ended have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 10th Nov 2023
- This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- The company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable
- The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 - "Earning per Share"
- The results are not comparable on quarterly or yearly basis as company is regularly incurring capex and filling dossiers with regulatory authorities.
- Limited review report has been carried out by the Statutory Auditors for the above period.
- The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.

Place: New Delhi

Date : 10.11.2023

For Medicamen Biotech Limited

Sd/-

Rahul Bishnoi

Chairman